3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Ovarian Neoplasms
4
Fallopian Tube Neoplasms
4
Sarcoma
1
Ovarian Cancer Recurrent
1
Cystadenocarcinoma, Serous
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Hepatocellular
1
Interventions
Sorafenib
8
Oxaliplatin
7
Bevacizumab
6
sintilimab
5
lenvatinib
5
apatinib
5
Fluorouracil
5
Capecitabine
5
atezolizumab
4
Leucovorin
4
Folfox protocol
4
camrelizumab
3
Drug Therapy
3
tremelimumab
2
durvalumab
2
Thalidomide
2
Radiosurgery
2
Nivolumab
2
Neoadjuvant Therapy
2
Injections
2
Hepatectomy
2
Gemcitabine
2
Ethiodized Oil
2
regorafenib
1
pirarubicin
1
pembrolizumab
1
menatetrenone
1
liposomal doxorubicin
1
lanreotide
1
halofantrine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Carcinoma, Hepatocellular
×
liposomal doxorubicin
×
Clear all
NCT02527772
2019-06-04
LD-FOX4/HCC
Guangxi Medical University
Phase 2/3
Withdrawn